Bexsero

Australia approves meningococcal B vaccine

Thursday, 15 August 2013

The Therapeutic Goods Administration has licensed the Novartis meningococcal B vaccine Bexsero for use in Australia.

The next steps will involve the Australian Technical Advisory Group on Immunisation making recommendations of who should receive the vaccine on the National Immunisation Programme to the Minister for Health and Ageing, and Novartis working with regulatory authorities to make the vaccine available for private purchase in Australia.

Meningococcal disease in Australia is predominantly caused by serogroup B. In contrast, most meningococcal disease in New Zealand is caused by serogroup B or serogroup C.

Show in archive
Archived: 
0
Audience: 
Archive Date: 

New meningococcal B vaccine in Europe

Friday, 25 January 2013

The European Commission has approved a new vaccine (Bexsero®) that provides broad protection against meningococcal group B disease.

In Europe, the vaccine has been licensed for use in individuals two months of age and older. The Therapeutic Goods Administration (TGA) in Australia is also reviewing the vaccine data and considering licensure of Bexsero® in Australia.

Bexsero® will complement the currently available meningococcal group C and groups A, C, Y and W-135 vaccines currently available.

Information about the disease is available on our Meningococcal disease webpage and in our fact sheet.

Show in archive
Archived: 
0
Audience: 
Archive Date: 
Subscribe to RSS - Bexsero